Bli medlem
Bli medlem
lakareutangranser

Du är här

2021-11-01

Redeye: Alzinova - Ready to ignite – Initiating clinical development

Redeye revisits the Alzinova equity story with the initiation of clinical trials with ALZ-101, its vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. Now is the time when the case could start to heat up. ALZ-101 is a candidate that stands out in a clinical pipeline that is set to gain increasing attention, thus, we have reviewed our financial forecasts and present an updated fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Alzinova - Ready to ignite – Initiating clinical development

Författare MFN